IDENTIFYING GERMLINE GENES AS TARGETS FOR THERAPEUTIC INTERVENTION IN CANCER
IDENTIFYING GERMLINE GENES AS TARGETS FOR THERAPEUTIC INTERVENTION IN CANCER
批准号:
8445954
负责人:
MARY LOU KING
金额:
$15.3万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-27 至 2014-08-31
关键词:
Antineoplastic AgentsApoptosisAreaBalbiani BodyBehaviorBiochemicalBiologicalBiological AssayBrainCadherinsCancer BiologyCancer cell lineCategoriesCell CycleCell DeathCell LineageCell divisionCell-Cell AdhesionCellular StructuresCharacteristicsDataDevelopmentDrosophila genusEmbryoEpithelialGene ExpressionGenesGeneticGermGerm Cell CancersGerm CellsGoalsImmunityLiquid ChromatographyMalignant NeoplasmsMesenchymalMitochondriaNeoplasm MetastasisOocytesOogenesisOrganismOutcomeProcessProteinsRNARNA Sequence AnalysisResearchScreening procedureSeminalSourceSpecific qualifier valueStructureTechnologyTestingTherapeutic InterventionTo specifyTumor Suppressor GenesVertebratesWorkXenopusanticancer researchbasecancer stem cellcancer therapydrug developmentexpression cloninggene functionneuronal cell bodynovelnovel markerscaffoldstem cell biologytandem mass spectrometrytherapeutic targettumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Recent progress in cancer research has highlighted a new category of targets for anti-cancer drugs: gene products expressed in the germline (Janic et al., 2010; Georlette et al., 2007; Wu and Ruvkun, 2010; Liu et al., 2011; Strumane et al., 2006; Caballero et al., 2009). Seminal work in Drosophila has shown that loss of a tumor suppressor gene causes brain malignancies that display a soma-to-germline transformation with 25% of up-regulated genes having a germline-associated function (Janic et al., 2010). Many of these tumor up-regulated genes are of maternal origin. Importantly, blocking the expression of these genes suppressed tumor growth. Germ cells share at least three important characteristics of cancer, the ability to: sustain a proliferative state, resist cell death, and undergo an epithelial-mesenchymal transition characteristic of invasion and metastasis. These findings strongly support the value of screening germ cell components for their ability to promote these behaviors as a step towards identifying potent therapeutic targets for cancer treatments. However, previous work on identifying germline components has relied almost entirely on RNA microarray data while the proteins remain largely unknown and the majority of RNAs uncharacterized, slowing progress in this area (Yatsu et al., 2008; Molyneaux et al., 2004; Ewen and Koopman, 2010). Germ plasm is the subcellular domain unique to germ cell precursors that contains all the determinants required to specify the germ cell lineage in diverse organisms. Our central hypothesis is that germ plasm will provide a rich source of new targets for anti-cancer drugs. Unfortunately, it is technically difficult to isolate germ plasm in sufficient quantities for proten analysis and thus, genetic information in vertebrates has been limited. Xenopus offers a unique opportunity to isolate biochemical quantities of germ plasm, making it possible, with current technology, to create a complete "parts list" of this cellular "machine" that specifies the totipotnt germ cell lineage. Moreover, Xenopus is highly amenable to expression cloning, allowing a high-throughput approach to assess gene function of germ plasm components. To test our central hypothesis, we will complete the following two specific aims: Aim 1. Identify the protein and RNA components of germ plasm and use this information to predict gene networks operating in the germline and up-regulated in cancer cell lines. Aim 2. Test these germ cell components for their ability to promote the biological "hallmarks" of cancer: metastasis, immortality, and proliferation in bioassays. In preliminary studies, we have isolated biochemical amounts of germ plasm and have identified over 400 proteins by Liquid Chromatography-tandem Mass Spectrometry analyses. We are now ready to launch into broader studies functionally screening germ plasm components for their possible relevance to cancer biology.
PUBLIC HEALTH RELEVANCE: Recent progress in cancer research has highlighted a new category of targets for anti-cancer drugs: gene products expressed in the germline. Our proposed research will identify and functionally screen such high value germline targets for their ability to promote the "hallmarks" of cancer: uncontrolled cell division, immunity to cell death, and metastasis. Our research will discover novel candidates for the development of new anti-cancer drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Translational Regulators Nanos and Dazl in Preserving Totipotency
-
批准号:8506391
-
项目类别:
-
资助金额:$36.82万
-
财政年份:2013
-
负责人:MARY LOU KING
-
依托单位:
Role of Translational Regulators Nanos and Dazl in Preserving Totipotency
-
批准号:8636488
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2013
-
负责人:MARY LOU KING
-
依托单位:
IDENTIFYING GERMLINE GENES AS TARGETS FOR THERAPEUTIC INTERVENTION IN CANCER
-
批准号:8554776
-
项目类别:
-
资助金额:$14.52万
-
财政年份:2012
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:7988443
-
项目类别:
-
资助金额:$13.27万
-
财政年份:2009
-
负责人:MARY LOU KING
-
依托单位:
LOCALIZED RNAS--DORSAL AND GERM CELL DETERMINANTS
-
批准号:2177197
-
项目类别:
-
资助金额:$26.17万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
CHARACTERIZATION OF LOCALIZED MATERNAL MRNA
-
批准号:3284139
-
项目类别:
-
资助金额:$10.35万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
LOCALIZED MATERNAL MRNA
-
批准号:2177195
-
项目类别:
-
资助金额:$24.45万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
LOCALIZED MATERNAL MRNA
-
批准号:2177196
-
项目类别:
-
资助金额:$25.54万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
CHARACTERIZATION OF LOCALIZED MATERNAL MRNA
-
批准号:3284140
-
项目类别:
-
资助金额:$23.74万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
CHARACTERIZATION OF LOCALIZED MATERNAL MRNA
-
批准号:3284138
-
项目类别:
-
资助金额:$10.52万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:6709397
-
项目类别:
-
资助金额:$32.57万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:6331219
-
项目类别:
-
资助金额:$34.42万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
CHARACTERIZATION OF LOCALIZED MATERNAL MRNA
-
批准号:3284134
-
项目类别:
-
资助金额:$22.08万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
LOCALIZED RNAS--DORSAL AND GERM CELL DETERMINANTS
-
批准号:2444582
-
项目类别:
-
资助金额:$25.71万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:7448442
-
项目类别:
-
资助金额:$34.91万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
CHARACTERIZATION OF LOCALIZED MATERNAL MRNA
-
批准号:3284141
-
项目类别:
-
资助金额:$5.83万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:7144675
-
项目类别:
-
资助金额:$34.31万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:7633327
-
项目类别:
-
资助金额:$34.91万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
LOCALIZED RNAS--DORSAL AND GERM CELL DETERMINANTS
-
批准号:2734506
-
项目类别:
-
资助金额:$26.5万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
Establishing Germ Cell Fate in Xenopus
-
批准号:6519152
-
项目类别:
-
资助金额:$32.57万
-
财政年份:1988
-
负责人:MARY LOU KING
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: